buprenorphine/naloxone sublingual film / Generic mfg. - LARVOL DELTA

Rapid microinduction of buprenorphine/naloxone for opioid use disorder in a large safety net hospital: a retrospective case series. (PubMed, Am J Drug Alcohol Abuse) - "There were zero cases of precipitated withdrawal. These findings support the safety and feasibility of buprenorphine microinductions in hospitalized patients with OUD, pain, and complicated medical presentations. This strategy allows adequate pain control while simultaneously transitioning to buprenorphine within three days, leading to improved retention, safety, and comfort."

Journal • Retrospective data • Addiction (Opioid and Alcohol) • CNS Disorders • Pain • Substance Abuse

Lived Experiences of Medication for Opioid Use Disorder: Clients' Perspectives on Formulation and Treatment. (PubMed, Subst Use) - "This study aimed to explore clients' perceptions and experiences of using oral Suboxone and injectable Vivitrol for OUD treatment. Our study provides valuable insights drawn from clients' experiences using oral and injectable MOUD in substance use treatment facilities. The findings will be useful for healthcare providers and policymakers to consider the pros and cons of these medications in substance use treatment settings."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Substance Abuse

Evaluating the abuse potential of gabapentin in combination with buprenorphine using conditioned place preference in mice (Neuroscience 2025) - "These medications include methadone or suboxone (buprenorphine)...Mice were randomly assigned to one of 13 groups consisting of 8-14 mice, including; saline/saline, morphine/saline, GBP (100 or 300 mg/kg)/saline, BUP/saline, buprenorphine+GBP 100 or 300 mg/kg/saline, naltrexone/saline, naltrexone+GBP 100 or 300/saline, naltrexone/BUP and lastly, naltrexone+GBP 100 or 300+BUP/saline...The results of this research indicate that GBP may have significant abuse potential alone and when combined with buprenorphine. The results also indicate that the rewarding effects GBP may be mediated by activity on opiate receptors."

Combination therapy • Preclinical • Addiction (Opioid and Alcohol) • CNS Disorders • Psychiatry

METHYLNALTREXONE-INDUCED OPIOID WITHDRAWAL CASE REPORT (CHEST 2025) - "He was not currently on methadone or suboxone at time of arrival. In the hospital, patient was started on methadone alongside ketamine, oxycodone and nonopioid agents...Patient tolerated the initial dilaudid well with improvement of his symptoms... Our case today highlights a rare occurrence of methylnaltrexone inducing opioid withdrawals which illustrates that further additional studies are needed to better understand other mechanisms of action that could have triggered this event."

Case report • Clinical • Cardiovascular • Constipation • Gastroenterology • Gastrointestinal Disorder • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Postoperative Transversus Thoracic Muscle Plane Catheters for Refractory Pain After Cardiac Surgery (ASA 2025) - "Our patient had a history of IVDU (heroine) on suboxone, endocarditis, and torrential TR...Despite maxing out the doses of several multimodals and a dilaudid PCA, she continued to have severe refractory anterior chest wall pain that was not relieved with medications. Her pain was inhibiting her from taking adequate deep breaths and working with PT. She received bilateral TTP PNC's on POD 1 and had immediate, significant relief of her pain."

Surgery • Cardiovascular • Pain

Awake Tracheostomy Under High-Dose Dexmedetomidine in a Patient with Severe Anxiety (ASA 2025) - "We present a case of sedated tracheostomy in a highly anxious patient with a history of opioid use disorder on high dose suboxone. A high-dose dexmedetomidine (10 mcg/kg/hr) infusion enabled sedation with preserved spontaneous ventilation. This case underscores key considerations in choosing between awake intubation and tracheostomy, and reviews literature-based strategies to manage anxiety during awake airway procedures.DOI: 10.1097/00000542-200409000-00028"

Clinical • Anesthesia • Mood Disorders • Psychiatry • Substance Abuse

HEROES: Houston Emergency Opioid Engagement System (clinicaltrials.gov) - P4 | N=3000 | Enrolling by invitation | Sponsor: The University of Texas Health Science Center, Houston | N=1500 ➔ 3000 | Trial completion date: Aug 2025 ➔ Aug 2030 | Trial primary completion date: Aug 2025 ➔ Aug 2030

Enrollment change • Trial completion date • Trial primary completion date • Substance Abuse

YHEROES: Young Houston Emergency Opioid Engagement System (clinicaltrials.gov) - P4 | N=250 | Recruiting | Sponsor: The University of Texas Health Science Center, Houston | N=15 ➔ 250 | Trial completion date: Aug 2027 ➔ Aug 2030 | Trial primary completion date: Aug 2026 ➔ Aug 2030

Enrollment change • Trial completion date • Trial primary completion date • Addiction (Opioid and Alcohol) • CNS Disorders • Substance Abuse

Buprenorphine/Naloxone therapy for opioid withdrawal, medication-assisted treatment, and pain management in an adolescent patient (AAP-NCE 2025) - "We present a case of a 17-year-old male who received treatment with buprenorphine-naloxone (Suboxone) for withdrawal management, MAT and acute pain.Case Description: A 17-year-old-male with a history of anxiety, depression, and attention deficit/hyperactivity disorder (ADHD) presented to the emergency department (ED) for increasing poly-substance use and acute withdrawal symptoms...His urine drug screen was positive for amphetamines, cannabinoids and tramadol metabolites and negative for other opioids...He required an increase in scheduled doses, addition of as-needed buprenorphine-naloxone for high clinical opioid withdrawal score (COWS) and symptomatic treatment with clonidine...He was managed non-operatively in the pediatric ICU with oxycodone and hydromorphone for acute pain... This case highlights the various indications of buprenorphine-naloxone in the adolescent population — withdrawal, MAT and acute pain. Pediatric providers may consult pain/addiction providers..."

Clinical • Addiction (Opioid and Alcohol) • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Depression • Mood Disorders • Pain • Pediatrics • Psychiatry

INDV-6001 Multiple-Dose Pharmacokinetic Study (clinicaltrials.gov) - P2 | N=122 | Active, not recruiting | Sponsor: Indivior Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Substance Abuse

Transforming patient care by equipping healthcare providers with the iPill ecosystem, an innovative in-home solution that ensures precise medication dispensing, real-time patient and medication adherence monitoring, and an unparalleled peace of mind. (PAINWeek 2025) - " Six patients were chosen and consented for the study who were on a maintenance Suboxone dose of 16 mg per day... All 6 patients operated the iPill dispenser for 30 days correctly. No tampering detected iPill Dispenser was detected. 2 patients were detected to have missed their daily dose and alerts were sent to the family, friends and caregiver."

Adherence • Clinical • Addiction (Opioid and Alcohol) • CNS Disorders • Substance Abuse

Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) (clinicaltrials.gov) - P2 | N=1516 | Active, not recruiting | Sponsor: NYU Langone Health | N=2190 ➔ 1516

Enrollment change • Substance Abuse

A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Rachel R. Luba | Not yet recruiting ➔ Recruiting

Enrollment open • Substance Abuse

Low-Dose Buprenorphine Initiation in Acute Burn Setting, a Retrospective Chart Review. (PubMed, J Burn Care Res) - "Incidentally, we also note that buprenorphine initiation was also associated with reduced opioid prescribing at discharge, with only 50% of our patient cohort requiring a brief short-acting taper in addition to buprenorphine. Further studies should address long-term outcomes in the patient population as well as how to best holistically manage patients with substance use disorder and concurrent burn injuries."

Journal • Retrospective data • Pain • Substance Abuse

Biomarkers associated with risk of negative clinical outcomes in people living with HIV on opioid replacement therapy (IAS-HIV 2025) - "To address the knowledge gap, we sought to identify inflammatory and immune biomarkers in PWH on opioid replacement therapy, including full (methadone, MET) or partial agonists (suboxone, SUB) of the µ-opioid receptor (MOR), and to assess a possible association with clinical outcomes. The study enrolled 3 virally suppressed PWH groups that included control (ART alone, n=14), SUB (ART+SUB, n=15), and MET (ART+MET, n=14) groups. These data suggest that PWH chronically exposed to MOR agonists have higher levels of specific circulating protein biomarkers that may be linked to increased risk of negative clinical outcomes."

Biomarker • Clinical • Clinical data • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Congestive Heart Failure • Dementia • Heart Failure • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Nephrology • Renal Disease • CXCL12 • IGLL1 • ROR1

A Case of Sudden Onset Diabetic Ketoacidosis in Pregnancy (ENDO 2025) - "Clinical Case: 31-year-old female (G3P0110) with history of substance use disorder (managed with suboxone), hepatitis C, and morbid obesity (BMI >35) presented at 37 weeks and 6 days gestation with intrauterine fetal demise in the setting of severe diabetic ketoacidosis (DKA)... We describe a case of rapidly developing diabetes in a pregnant patient with otherwise normal antepartum testing (GCT and urine glucose), 28 lb weight gain in pregnancy, normal fetal growth, and an absence of diabetes-related symptoms until 37 weeks gestation. While this case does not meet all criteria for fulminant diabetes in pregnancy, it suggests that repeated diabetes screening should be considered in patients with high-risk clinical features, such as obesity and prediabetes, in order to avoid late-term maternal and fetal complications."

Clinical • Genetic Disorders • Gestational Diabetes • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Metabolic Disorders • Obesity • Type 1 Diabetes Mellitus

Severe intravenous buprenorphine/suboxone® use disorder: a case report. (PubMed, J Addict Dis) - No abstract available

Journal

Information Needs for Opioid Use Disorder Treatment Using Buprenorphine Product: Qualitative Analysis of Suboxone-Focused Reddit Data. (PubMed, J Med Internet Res) - "Our findings can guide the design of interventions to improve patient education and communication. They also help address knowledge gaps and misinformation related to treatment. Additionally, the results can support hypothesis generation for future clinical research on medication for opioid use disorder treatment."

Journal • Addiction (Opioid and Alcohol) • Substance Abuse

Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency Departments (clinicaltrials.gov) - P2/3 | N=658 | Recruiting | Sponsor: University of British Columbia | Trial completion date: Jun 2025 ➔ Jun 2027 | Trial primary completion date: Dec 2024 ➔ Dec 2026

Trial completion date • Trial primary completion date • Substance Abuse

Exploratory Analysis on the Role of Video Tools and Multidisciplinary Healthcare Providers to Aid Counselling for Buprenorphine/Naloxone Induction Within the Evaluating Microdosing in the Emergency Department Study. (PubMed, Cureus) - "Conclusion We can improve patient access to buprenorphine/naloxone induction counselling by utilizing an adjunct video tool and distributing workload between emergency physicians and clinical pharmacists. Future sites interested in providing take-home buprenorphine/naloxone kits may benefit from implementing video tools and involving clinical pharmacists to mitigate workflow burdens."

Journal • Video • Substance Abuse

Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) (clinicaltrials.gov) - P2 | N=2190 | Active, not recruiting | Sponsor: NYU Langone Health | Recruiting ➔ Active, not recruiting

Enrollment closed • Substance Abuse

Suboxone Dispenser for OUD (clinicaltrials.gov) - P=N/A | N=0 | Withdrawn | Sponsor: Addinex Technologies, Inc. | N=10 ➔ 0 | Trial completion date: Jun 2025 ➔ Aug 2024 | Recruiting ➔ Withdrawn | Trial primary completion date: Mar 2025 ➔ Aug 2024

Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Substance Abuse

Noxious Inhalation Lung Injury in the Setting of E-cigarette/Vaping Use (ATS 2025) - "Case Report: A 35-year-old man with a past medical history of OSA (not on CPAP), IV-heroine drug use (drug-free for 8 years and on Suboxone), Chronic Hepatitis C infection (not on any medications),current cigarette smoker with vaping for over 15 years and cholecystectomy presented to the Emergency Department (ED) with worsening dyspnea and tactile fevers for less a day with an episode of non-bloody vomiting, chronic vague, diffuse abdominal discomfort, and recent exposure to sick contacts...The patient was started on 2L of oxygen via nasal cannula, given Ceftriaxone, Azithromycin, Methylprednisolone and Duo-Nebulizers...Future research prospects are currently oriented around identifying exposure-related and disease-related biomarkers to further characterize the pathogenesis and pathophysiology of EVALI. In essence, this case report highlights a critical respiratory syndrome underscored by its recent and rapid emergence in the clinical setting which necessitates further..."

Cardiovascular • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Pulmonary Disease • Respiratory Diseases • CRP

Barriers to Psychiatric Care Among Refugees: A Literature Review (APA 2025) - "He sought psychiatric care and rehabilitation while in Turkey where he was maintained on suboxone therapy. Once he immigrated to the United States, the unknown of how to seek psychiatric help due to language barriers and socio-economical struggles, led to him relapsing and further using fentanyl due to ease and accessibility...Overcoming the barriers patients' face when trying to seek psychiatric treatment is essential to help promote mental health equity to all. Although this is an issue among non-refugee individuals, it is further confounded with the lack of status or access to care in certain localities."

Review • CNS Disorders • Depression • Mood Disorders • Post-traumatic Stress Disorder • Psychiatry • Substance Abuse

"Catch Me When You Can": Suboxone Screening and Induction in the Psychiatric ER (APA 2025) - "We will finish with a summary of our intervention and future directions. Instructional Level Introductory; Learning Objectives Objective One: Learn about screening tools for OUD in the psychiatric ER Objective Two: Learn about challenges faced and interventions to manage initiating buprenorphine in the ER Objective Three: Learn about buprenorphine induction and maintenance while in the psychiatric ER Objective Four: Objective Five:; Objective One: Learn about screening tools for OUD in the psychiatric ER; Objective Two: Learn about challenges faced and interventions to manage initiating buprenorphine in the ER; Objective Three: Learn about buprenorphine induction and maintenance while in the psychiatric ER; Objective Four:; Objective Five:"

Addiction (Opioid and Alcohol) • Psychiatry • Substance Abuse